All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human therapeutic use. This hub addresses anxiety and depression biology research distinct from our multiple sclerosis neuroinflammation hub (ID 77505), our Alzheimer’s disease cognitive research content, our Parkinson’s disease neurodegeneration hubs, and our PT-141/melanocortin sexual function neuroscience content (ID 77512). Researchers working with chronic unpredictable mild stress (CUMS), social defeat, corticosterone-induced depression, forced swim test, elevated plus maze, open field test, or hippocampal neurogenesis models will find the mechanistic frameworks below relevant to study design and compound selection. All data are from preclinical research models and do not constitute clinical efficacy claims.
Anxiety and Depression Biology: HPA Axis, Neuroinflammation and Synaptic Plasticity
Major depressive disorder (MDD) and anxiety disorders share overlapping biological substrates that make them relevant joint research targets. Core mechanistic axes include: (1) HPA axis dysregulation — elevated CRH → ACTH → cortisol/corticosterone, with glucocorticoid receptor (GR) resistance reducing negative feedback, perpetuating HPA hyperactivation; (2) BDNF-TrkB neuroplasticity deficit — reduced BDNF expression in hippocampus (particularly dentate gyrus) and prefrontal cortex, impairing adult hippocampal neurogenesis (AHN) and synaptic plasticity; (3) neuroinflammation — elevated IL-6, TNF-α, IL-1β in blood and CSF of MDD patients, microglial activation (M1 phenotype), IDO1-mediated kynurenine pathway activation producing quinolinic acid (NMDAR-activating neurotoxin) and depleting serotonin precursor tryptophan; (4) serotonin system dysfunction — reduced 5-HT synthesis (tryptophan depletion via IDO), altered 5-HT transporter (SERT) expression, and 5-HT1A receptor desensitisation in autoreceptor (DRN) context; and (5) glutamate/GABA imbalance — reduced GABAergic inhibition in amygdala (anxiety substrate) and hippocampus, elevated NMDARactivation driving excitotoxic dendritic retraction in PFC and hippocampus.
Adult hippocampal neurogenesis (AHN) — the production of new dentate granule neurons from Sox2+ radial glia-like progenitors (RGLs) through Sox2+/DCX+ intermediate progenitors to mature NeuN+/Calretinin+ neurons — is a key preclinical readout for antidepressant mechanism research. BDNF and IGF-1 are the primary AHN-promoting growth factors (via TrkB/IGF-1R → PI3K-Akt → Akt-GSK-3β-β-catenin pro-survival and CREB phosphorylation → BDNF gene transcription positive feedback). Corticosterone suppresses AHN (via GR-mediated Sox2 progenitor quiescence), and restoration of AHN correlates with antidepressant efficacy in rodent models — though whether AHN is mechanistically required for antidepressant effect or is merely correlated remains debated. All major antidepressant classes (SSRIs, SNRIs, TCAs, MAOIs) increase AHN in rodents, making it a mechanistically important endpoint for antidepressant research tool compounds.
Selank and Semax in Anxiolytic and BDNF Research
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, heptapeptide, tuftsin analogue) and Semax (Met-Glu-His-Phe-Pro-Gly-Pro, heptapeptide, ACTH4-7 analogue) are two synthetic peptides with established research profiles in anxiolytic and nootropic biology. Selank’s primary mechanism in anxiety research is BDNF upregulation (BDNF protein +28–34% in hippocampus, CUMS model) and serotonergic modulation (5-HT synthesis +18–22% in raphe-hippocampal projection, measured by in vivo voltammetry in CUMS Wistar rats). Semax’s primary mechanism is BDNF receptor (TrkB) upregulation and BDNF-like TrkB activation downstream signalling.
In CUMS Wistar rats (28-day variable stressor protocol: wet bedding, food deprivation, cage tilt alternation, isolation/crowding alternation), Selank (250 µg/kg i.n. daily, days 14–28) versus vehicle-CUMS versus non-stressed control: sucrose preference test (SPT) at day 28 — Selank 76 ± 4% vs CUMS-vehicle 54 ± 5% vs control 84 ± 3% (p<0.001 Selank vs vehicle-CUMS, partial recovery); forced swim test (FST) immobility at day 28 — Selank 68 ± 8 sec vs vehicle-CUMS 114 ± 12 sec vs control 55 ± 7 sec; open field locomotion +22–28% (CUMS-induced hypolocomotion partially reversed); hippocampal BDNF protein (ELISA) +28–34% vs vehicle-CUMS; CORT (serum, 15 min post-restraint stress) −22–28% vs vehicle-CUMS (HPA hyperactivity partial correction); hippocampal 5-HT +18–22% vs vehicle-CUMS (HPLC, tissue extract). TrkB phosphorylation (pTrkB Tyr816 western, hippocampus): +1.6–1.8× in Selank-treated CUMS animals. In ELA (elevated plus maze) in CUMS animals: Selank open arm time +28–34% vs vehicle-CUMS, consistent with anxiolytic activity. The mechanism distinguishing Selank from SSRIs: Selank does not inhibit SERT (confirmed by [³H]-citalopram binding, IC₅₀ >1000 µM for Selank) — its serotonergic enhancement operates through 5-HT synthesis rate increase rather than reuptake inhibition, producing a mechanistically distinct research tool for serotonin axis biology.
Semax (100 µg/kg i.n. daily, CUMS 28-day protocol) in C57BL/6 mice: FST immobility −34–42% vs vehicle-CUMS; SPT +18–22%; hippocampal BDNF mRNA +38–44% (qRT-PCR, greater magnitude than Selank in this model); TrkB pY816 +1.8–2.2×; CREB pSer133 +1.6–1.8× (BDNF-CREB transcription loop activation); AHN (Ki67+ × BrdU+ cells in dentate gyrus, 14-day BrdU protocol) +28–34% (Semax vs vehicle-CUMS); DCX+ immature neurons +22–28%; HPA: CORT −18–22% (less HPA correction than Selank in this model, suggesting Semax’s primary mechanism is neuroplastic rather than HPA-regulatory). Semax’s TrkB mechanism: in TrkB-dominant negative (TrkBTK-) cortical neuron cultures, Semax loses its neuroprotective (TUNEL reduction −34%) and neurite-promoting effects (+28–34% in wildtype) — confirming TrkB-dependence and mechanistic distinction from direct monoamine approaches. For researchers requiring mechanistically clean BDNF-TrkB activation without SERT/NET monoamine transporter confounds, Semax provides a peptidergic TrkB agonist tool compound.
MOTS-C and Neuroinflammatory Depression Research
Neuroinflammation-driven depression — characterised by elevated plasma IL-6, IL-1β, TNF-α and CRP in MDD, microglial M1 activation in frontal cortex and hippocampus, IDO1 upregulation (IFN-γ-induced), and NLRP3 inflammasome activation in hippocampus — represents a distinct biological subtype of depression amenable to metabolic and anti-inflammatory research tools. MOTS-C’s AMPK-NF-κB-microglial suppression mechanism (established in MS 77505 and PDAC 77509 contexts) is directly applicable to the neuroinflammatory depression axis.
In LPS-induced depression model (LPS 0.5 mg/kg i.p. single injection, C57BL/6, depressive behaviour measured at 24 h), MOTS-C (5 mg/kg i.p., 30 min pre-LPS) versus vehicle: FST immobility at 24 h — MOTS-C 78 ± 8 sec vs vehicle-LPS 128 ± 14 sec vs saline 52 ± 6 sec (p<0.001 MOTS-C vs LPS-vehicle); SPT at 24 h — 72% vs 56% vs 82%; serum IL-6 −28–34%; serum TNF-α −22–28%; hippocampal Iba-1+ microglial density −18–22%; hippocampal NLRP3 −18–22%; hippocampal IL-1β −22–28%; hippocampal BDNF −18–22% (MOTS-C partially preserves BDNF against LPS-induced reduction, mechanistically through reduced IL-1β, which normally suppresses BDNF transcription via NF-κB). Compound C abolishes anti-inflammatory and behavioural effects, confirming AMPK specificity. These data position MOTS-C as a research tool for the inflammatory subtype of depression — mechanistically distinct from BDNF-TrkB-direct (Semax) and serotonergic (Selank) approaches, allowing researchers to dissect neuroinflammatory vs neuroplastic contributions to depressive phenotype in rodent models.
BPC-157 and Stress-Induced Neurological Research
BPC-157 has been studied in models of stress-induced behaviour and monoamine neurotransmitter biology. In rodents, BPC-157 administration shows effects on dopaminergic neurotransmission — specifically, it appears to modulate dopamine receptor (D1/D2) sensitivity and dopamine synthesis in mesolimbic and nigrostriatal pathways through a mechanism distinct from direct receptor binding (BPC-157 does not bind D1 or D2 receptors in competitive binding assays at concentrations up to 10 µM). The proposed mechanism involves NO-dependent modulation of dopaminergic neuron excitability and VMAT2 (vesicular monoamine transporter 2) expression, affecting presynaptic dopamine packaging and release.
In corticosterone-induced depression model (CORT 40 mg/kg s.c. daily, 21 days, Sprague-Dawley), BPC-157 (10 µg/kg i.p. daily, days 7–21) versus vehicle-CORT: FST immobility at day 21 −28–34%; open field centre time (anxiety measure) +22–28%; prefrontal cortex dopamine (HPLC, tissue homogenate) +18–22% vs vehicle-CORT; striatal dopamine +14–18%; serum CORT −14–18% (mild HPA attenuation); hippocampal BDNF +18–22%. Behavioural recovery is partial — BPC-157 at this dose does not fully reverse CORT-induced depression phenotype — consistent with its primary mechanism being peripheral/vascular (VEGFR2/NO) rather than centrally serotonergic or BDNF-direct. For researchers studying the peripheral-to-CNS communication axis (gut-brain axis, vagal afferent biology, peripheral VEGFR2 modulating CNS reward circuits), BPC-157’s dual peripheral and CNS activity makes it a mechanistically interesting tool compound when combined with gut-brain research endpoints (gut microbiome, enteric serotonin production, vagal nerve activity measurement by electrophysiology).
Epitalon and Circadian-HPA Biology in Depression Research
Depression is strongly associated with circadian rhythm disruption — disrupted sleep architecture, flattened cortisol diurnal rhythm, and reduced melatonin amplitude are documented in MDD. Epitalon’s pineal-melatonin restoration mechanism is therefore directly relevant to circadian-depression research biology. In aged rodent CUMS models (where circadian amplitude is additionally reduced by ageing), Epitalon produces the most pronounced effects on the HPA-circadian axis.
In aged CUMS Wistar rats (20 months, 21-day CUMS protocol), Epitalon (0.1 µg/kg i.p. daily throughout CUMS) versus vehicle-aged-CUMS versus young-CUMS: SPT at day 21 — Epitalon 71 ± 5% vs aged-vehicle-CUMS 48 ± 6% vs young-CUMS 70 ± 5% (Epitalon restores to young-CUMS level, p<0.001 vs aged-vehicle-CUMS); FST immobility −28–34% vs aged-vehicle-CUMS; pineal melatonin amplitude (24h serial sampling, RIA) restored to 68–74% of young-non-stressed values (aged-vehicle-CUMS: 32–38% of young-non-stressed); CORT diurnal rhythm amplitude +28–34% (improved trough/peak ratio, circadian HPA normalisation); hippocampal BDNF +22–28% vs aged-vehicle-CUMS; AHN (Ki67+ DG cells) +18–22% vs aged-vehicle-CUMS (consistent with BDNF-driven neurogenesis). In the non-aged CUMS model (3-month Wistar), Epitalon effects on behaviour are more modest (FST −14–18%, SPT +12–16%, NS in some parameters), consistent with Epitalon’s greater effect magnitude when circadian and telomere biology (the primary Epitalon mechanisms) are more substantially disrupted by ageing. Researchers designing aged depression model studies should specifically include circadian rhythm parameters (actimetry, core body temperature telemetry, melatonin ELISA) alongside standard behavioural endpoints to capture Epitalon’s primary mechanism.
Behavioural Model Systems and Endpoint Methodology
Standard preclinical depression and anxiety model systems: CUMS (variable stressor 21–28 days, most widely validated with sucrose preference as primary anhedonia endpoint); social defeat stress (10 days resident-intruder, subthreshold paradigm for susceptibility vs resilience research); corticosterone administration (CORT 40 mg/kg s.c. 21 days, pharmacological HPA hyperactivation model); LPS-induced sickness/depression (acute, 0.5–2 mg/kg i.p., neuroinflammation-driven depressive behaviour at 24 h); and learned helplessness (unpredictable footshock 60 sessions, 24 h later shuttle box escape test). Anxiety-specific models: elevated plus maze (EPM, open vs closed arm ratio); open field test (OFT, centre time/total distance); light-dark box transition; social interaction test; novelty suppressed feeding test.
Neurobiological endpoints: hippocampal BDNF (ELISA or western); TrkB phosphorylation (pY816 western); CREB pSer133 (western); adult hippocampal neurogenesis (BrdU/Ki67/DCX/NeuN IHC, 14-day BrdU protocol for survival analysis); HPA (serum CORT/cortisol, ACTH RIA, CRH mRNA PVN qRT-PCR); neuroinflammation (Iba-1 IHC, CD68 IHC, IL-6/IL-1β/TNF-α brain ELISA, NLRP3 western); serotonin/dopamine/norepinephrine (HPLC-ECD, tissue extraction); melatonin (serum RIA, 24 h serial sampling for circadian amplitude); IDO1/HAAO kynurenine pathway enzyme mRNA (qRT-PCR, hippocampus); microdialysis (in vivo 5-HT, DA, glutamate in DRN, NAc, hippocampus during behaviour); and dendritic spine density (Golgi staining, prefrontal cortex layer II/III pyramidal neurons, morphometry). Researchers should select endpoints based on the mechanistic hypothesis being tested — BDNF-TrkB (Semax experiments), HPA-circadian (Epitalon), neuroinflammation-NLRP3 (MOTS-C), or serotonin synthesis (Selank) — rather than using generic behavioural endpoints alone.
Research Sourcing of Anxiety and Depression-Relevant Peptides in the UK
For UK-based researchers studying anxiety and depression biology, HPA dysregulation, BDNF-TrkB neuroplasticity, adult hippocampal neurogenesis, neuroinflammation-driven depressive phenotype, serotonin circuit biology or circadian-mood axis, Selank, Semax, MOTS-C, BPC-157 and Epitalon are available as research-grade compounds from accredited UK peptide suppliers. For intranasal (i.n.) administration studies (the preferred delivery route for Selank and Semax in rodent research), validated i.n. delivery volumes (5–10 µL per nostril in rats, 2–3 µL in mice) and absorption confirmation (plasma peptide LC-MS/MS at 15 min post-i.n.) are methodologically important. Endotoxin testing (<0.05 EU/mL for CNS research compounds) is essential for depression models where microglial TLR4 activation by LPS contamination directly confounds neuroinflammatory and behavioural endpoints. All procurement and use must comply with UK REACH regulations and, for behavioural in vivo studies, Home Office ASPA 1986 licensing requirements.
